Production of bispecific antibodies: Diabodies and tandem scFv

Methods in Molecular Biology

Volumn 907, Issue , 2012, Pages 713-727

  Hornig, Nora ^a   Färber Schwarz, Aline ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Antibody formats; Bacterial production; Bispecific diabody; Cloning strategies; Recombinant antibody molecules; scFv; Tandem scFv; Variable domains

Indexed keywords

EID: 84867803659     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-974-7_40     Document Type: Article

References (21)

1. Withoff S et al (2001) Bispeci fi c antibody therapy for the treatment of cancer. Curr Opin Mol Ther 3:353-362
2. Segal DM et al (1999) Bispeci fi c antibodies in cancer therapy. Curr Opin Immunol 11:558-562
3. Cochlovius B et al (2000) Cure of Burkitt's lymphoma in severe combined immunode fi ciency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res 60:4336-4341
4. Kontermann RE (2005) Recombinant bispecifc antibodies for cancer therapy. Acta Pharmacol Sin 26:1-9
5. Cao Y, Suresh MR (1998) Bispeci fi c antibodies as novel bioconjugates. Bioconjug Chem 9(6):635-644
6. Löf fl er A et al (2000) A recombinant bispeci fi c single-chain antibody, CD19 × CD2, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95: 2098-2103
7. Nettelbeck D et al (2001) Retargeting of adenoviruses to endothelial cells by a speci fi c singlechain diabody directed against the adenovirus knob domain and human endoglin (CD105). Mol Ther 3:882-891
8. Haisma HJ et al (2000) Targeting of adenoviral vectors through a bispeci fi c single-chain antibody. Cancer Gene Ther 7:901-904
9. Kriangkum J et al (2001) Bispeci fi c and bifunctional single chain recombinant antibodies. Biomol Eng 18:31-40
10. Kontermann RE, Völkel T, Korn T (2004) Production of recombinant bispeci fi c antibodies. In: Lo BKC (ed) Antibody engineering: methods and protocols, vol 248. Humana Press Inc., Totowa, New Jersey, pp 227-242
11. Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531-545
12. Stork R et al (2008) N-glycosylation as novel strategy to improve pharmacokinetic properties of bispeci fi c single-chain diabodies. J Biol Chem 283(12):7804-7812
13. Müller D et al (2007) Improved pharmacokinetics of recombinant bispeci fi c antibody molecules by fusion to human serum albumin. J Biol Chem 282(17):12650-12660
14. Stork R, Müller D, Kontermann RE (2007) A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispeci fi c single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 20(11):569-576
15. Lu D et al (2004) The effect of variable domain orientation and arrangement on the antigenbinding activity of a recombinant bispeci fi c diabody. Biochem Biophys Res Commun 318: 507-513
16. Holliger P (1993) "Diabodies", small bivalent and bispeci fi c antibody fragments. Proc Natl Acad Sci U S A 90:6444-6448
17. Perisic O et al (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217-1226
18. Carmichael J et al (2003) The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in VL-to-VH orientation: implications for diabody fl exibility. J Mol Biol 326:341-351
19. Korn T et al (2004) Recombinant bispeci fi c antibodies for the targeting of adenoviruses to CEA-expressing tumor cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6:642-651
20. Kranz DM, Gruber M, Wilson ER (1995) Properties of bispeci fi c single chain antibodies expressed in Escherichia coli. J Hematother 4:403-408
21. Hayden MS et al (1994) Single-chain monoand bispeci fi c antibody derivates with novel biological properties and antitumor activity from a COS cell transient expression system. Ther Immunol 1:3-15